ARWR
Arrowhead Pharmaceuticals, Inc.·Healthcare
65.14
1.646%(−1.09)
Market ClosedLast Updated: — ET
52W L: $10.9252W H: $76.76
ARWR NEWS
defenseworld.net
5d ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating
businesswire.com
Mar 28
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG). The data were presented by Dr. Christie M. Ballantyne, MD, professor at Baylor College of Medicine, member of the Texas Heart Institute at Baylor, and Principal Inve.
seekingalpha.com
Mar 26
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial stage, with its first approval for plozasiran in FCS. ARWR's valuation reflects a 5% downside, 10-15% base case upside, and up to 40% bull case upside, supporting a cautious buy rating. The investment thesis centers on a robust RNAi platform, late-stage cardiometabolic franchise, and significant near-term catalysts, notably SHTG phase 3 data.
defenseworld.net
Mar 10
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead
Arrowhead Pharmaceuticals (NASDAQ: ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second half of the year. Multiple clinical catalysts expected in the third quarter Chief Executive
defenseworld.net
Mar 9
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc.
Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 63.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,582 shares of the biotechnology company's stock after selling 89,204 shares during the period. Citigroup Inc.'s holdings in
gurufocus.com
Feb 24
GSK Strikes $1 Billion China RNA Deal
GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio
